Gossamer Bio Expects to Commence Global Registrational Phase 3 Trial of Seralutinib for Patients With PH-ILD in Mid-2025
Gossamer Bio Expects to Commence Global Registrational Phase 3 Trial of Seralutinib for Patients With PH-ILD in Mid-2025
gossamer bio預計在2025年中旬開始進行Seralutinib用於PH-ILD患者的全球註冊第三期試驗。
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊